Reporter visits Shanghai to see China’s fast‑growing biotech sector as Chinese‑designed drugs make up about half of the global pipeline

A STAT+ correspondent traveled to Shanghai to get a first‑hand view of the rapid expansion of China’s biotech industry. The piece describes the bustling research environment and the growing number of domestic drug programs.

The article notes that Chinese‑designed medicines now account for roughly half of the worldwide drug pipeline, underscoring the scale of the country’s investment in biotech.

The surge in Chinese drug development is portrayed as a source of unease for U.S. stakeholders, who see the competition intensifying.

The story appears as part of STAT+’s subscription‑only content, offering readers deeper analysis of the global biotech landscape.